Florida Cancer Specialists Expansion in Advanced Therapies
Florida Cancer Specialists & Research Institute, LLC (FCS) is proud to announce significant growth in the provision of advanced radiopharmaceutical therapies, designed to enhance the treatment possibilities for cancer patients. By launching services at more clinic locations, the specialists at FCS have successfully treated a variety of patients battling prostate and neuroendocrine cancers through targeted therapies.
Expanding Clinic Network
Recently, FCS has expanded its capabilities by introducing three FDA-approved radiopharmaceutical drugs at 14 locations statewide. The therapies, namely Pluvicto™, Xofigo, and LUTATHERA™, have seen substantial uptake, and plans are underway to open an additional clinic. The demand for these treatments has surged, with patient numbers and treatment administration doubling over recent years, highlighting the urgent need for such innovative approaches.
Effective Cancer Treatment Options
FCS' Radiopharmaceutical Therapy (RPT) program was initiated to meet the rising demand for effective cancer treatment methods. Since starting in 2022, it has treated nearly 400 patients, delivering over 1,000 therapeutic infusions. As more therapies become available, patient visits for treatments like Lutathera and Xofigo have increased significantly. This reflects both an effective marketing strategy and the life-saving potential of these treatments.
Direct Impact on Patients' Lives
“Radiopharmaceutical therapy offers new hope for cancer patients facing late-stage or recurrent conditions,” explained Dr. Sachin Kamath, Director of Radiation Oncology. This innovative therapy utilizes radioactive isotopes targeted directly at tumor cells, effectively killing or damaging them while minimizing harm to healthy tissue. Such precision in treatment is a leap forward in oncological therapy.
Details about Radiopharmaceutical Therapies
FCS offers three significant therapies for various types of cancer. Pluvicto™ targets prostate-specific membrane antigen-positive metastatic prostate cancer, while Xofigo specifically treats late-stage prostate cancer that has spread to the bones. LUTATHERA™ is unique as it is the only approved radiation treatment specific to adults with gastroenteropancreatic neuroendocrine tumors.
With prostate cancer accounting for a substantial number of cancer diagnoses in American men, advanced therapies like these are critical. According to resources, nearly 314,000 new cases of prostate cancer are expected to be diagnosed soon, with a notable percentage progressing to an advanced stage.
Rising Incidence of Neuroendocrine Tumors
Similarly, gastroenteropancreatic neuroendocrine tumors are becoming increasingly prevalent. The number of diagnoses continues to rise, emphasizing the importance of continuing advancements in treatment protocols. According to studies, the overall incidence increased nearly four percent between 2001 and 2020.
Access to Life-Changing Therapies
The U.S. Food and Drug Administration recently broadened access to Pluvicto™, allowing it for use in patients who have yet to undergo chemotherapy. This approval enhances the reach of this groundbreaking treatment and ensures more patients will benefit from its life-changing effects.
Moreover, Xofigo and LUTATHERA™ continue to play vital roles in the treatment of their respective cancers, providing patients with options they may not have had before. The continuous update and expansion of cancer treatments are a central focus for FCS, showcasing their commitment to patient care and cutting-edge technology.
Locations Offering Radiopharmaceutical Therapy
FCS is proud to now offer RPT at multiple locations, including:
- Brooksville
- Gainesville
- Gladiolus
- Good Samaritan Flagler
- Highland
- Naples Goodlette
- North Port
- Ocala
- Orlando
- St. Petersburg
- Tallahassee
- Tampa
- The Villages
- Trinity
- Wesley Chapel (Coming Soon!)
About Florida Cancer Specialists & Research Institute
Founded more than 40 years ago, Florida Cancer Specialists & Research Institute has a legacy of innovation in oncology care. FCS has made monumental strides in providing patients with access to clinical trials that often pave the way for new therapies to become available in the U.S. FCS takes pride in its team of highly trained physicians, committed to delivering individualized treatment plans that reflect groundbreaking advancements in precision oncology.
Frequently Asked Questions
What therapies are offered by Florida Cancer Specialists?
Florida Cancer Specialists offers FDA-approved therapies including Pluvicto™, Xofigo, and LUTATHERA™ for treating various types of cancer.
How has patient access to therapies changed?
Patient access has greatly improved, with the number of treatments administered doubling over the last few years due to increased availability of new therapies.
What is the purpose of radiopharmaceutical therapy?
Radiopharmaceutical therapy aims to target and kill tumor cells by delivering radiation directly to them, mitigating damage to healthy tissues.
How many locations offer these treatments?
Radiopharmaceutical therapies are currently offered at 14 locations, with plans for expansion.
What is FCS's mission?
Florida Cancer Specialists aims to provide innovative and advanced cancer treatment options, continuously improving patient outcomes and access to care.
